• Introduction to the Modular Next Gen Hyper15™ Delivery Platform, the first technology capable of bypassing the endosome to successfully deliver dual siRNA payloads directly to adipose tissue. This breakthrough enables precise genetic silencing within the fat cell itself, treating the tissue as a metabolic organ rather than just a storage depot.

Differentiating CCT-217 from standard-of-care incretins by moving “Beyond Appetite.” We present data showing how silencing adipose-specific genes at their mitochondrial receptors unlocks thermogenic energy expenditure and lipolysis, driving weight loss through metabolic upregulation rather than caloric restriction/starvation physiology.

A deep dive into the compositional and commercial advantage of CCT-217. We demonstrate how CCT-217 delivers Selective Fat Mass reduction and Muscle Enhancement—avoiding the sarcopenic trap of GLP-1s—while offering an Ultra-Long Duration dosing profile (6+ months) that redefines treatment adherence